Targeting MDM2-p53 interaction for cancer therapy: are we there yet?

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Inactivation of tumor suppressor p53 and overexpression of oncogene MDM2 are common in human cancers, correlating with poor prognosis and chemoresistance.
• MDM2 is a key negative regulator of p53, promoting its degradation and inhibiting its tumor-suppressive functions.
• The feedback loop between MDM2 and p53 is a validated target for cancer therapy, with inhibitors progressing to clinical trials.

Purpose of the Study:

• To review the multifaceted roles of the MDM2-p53 interaction in cancer development and progression.
• To explore the p53-independent oncogenic activities of MDM2.
• To summarize therapeutic strategies targeting MDM2 and the MDM2-p53 axis, including preclinical and clinical evidence of MDM2 inhibitors.

Main Methods:

• Literature review of preclinical and clinical studies on MDM2 and p53 in cancer.
• Analysis of the MDM2-p53 negative feedback loop and MDM2's p53-independent functions.
• Evaluation of current and emerging MDM2 inhibitors for cancer treatment.

Main Results:

• The MDM2-p53 pathway is frequently dysregulated in various human cancers, impacting disease progression and treatment response.
• MDM2 exhibits oncogenic activities independent of p53, contributing to carcinogenesis.
• MDM2 inhibitors have shown promise in preclinical and clinical settings, warranting further investigation and optimization.

Conclusions:

• Targeting the MDM2-p53 interaction and MDM2's oncogenic functions represents a promising therapeutic avenue for cancer.
• Further research is needed to enhance the efficacy and safety of MDM2 inhibitors.
• Understanding both p53-dependent and p53-independent roles of MDM2 is critical for developing effective cancer therapies.